Currently Viewing:
Newsroom
Currently Reading
Lack of Payer Support a Barrier to Diabetes Prevention, CDC Reports
December 17, 2017 – Mary Caffrey
Pfizer Announces Phase 3 Trial for Atopic Dermatitis Treatment
December 15, 2017 – Samantha DiGrande
Average Profit Margin on Oncology Drugs For 340B Hospitals Nears 50%
December 15, 2017 – Jaime Rosenberg
Majority of Women With Breast Cancer Surgery Did Not Feel Fully Informed of Treatment Options
December 15, 2017 – Jaime Rosenberg
AJMC® in the Press, December 15, 2017
December 15, 2017 – AJMC Staff
What We're Reading: Medicare Lab Testing; CHIP Deadline; AMA Expands Diabetes Efforts
December 15, 2017 – AJMC Staff
5 Key Takeaways From ASH 2017
December 15, 2017 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: December 15, 2017
December 15, 2017
What We're Reading: Medical Device Tax; Marijuana and Vaping; Birth Control Without Prescriptions
December 14, 2017 – AJMC Staff

What We're Reading: Iowa Seeks to Change ACA; Teaching About Drug Costs; FDA Rejects Neulasta Biosimilar

AJMC Staff

Iowa Proposes State Changes to ACA

In Iowa, officials are seeking to alter major parts of the Affordable Care Act (ACA). According to The Wall Street Journal, the state would revamp the ACA’s subsidies and offer just 1 type of insurance plan. The White House has already said it is open to state altering how the ACA works within a state’s borders. The Iowa Insurance Commissioner has called the proposal a stopgap that would only remain in place until Republicans in Congress pass a bill to change the ACA at the national level.

 

Educating Doctors on Drug Costs

A former drug salesman is teaching doctors about high drug costs in an effort to save millions of dollars. He works for Capital District Physicians’ Health Plan (CDPHP) and also educates doctors on the strategies used to sell expensive prescriptions, reported Kaiser Health News. Insurers are also taking other steps to fight back against rising drug costs, such as educating doctors on pill effectiveness or removing high-cost drugs from coverage. CDPHP is working to educate doctors on prices because they are often unaware of the cost of the treatments they order.

 

FDA Declines Approval of Neulasta Biosimilar

Amgen may have lost its biosimilar case before the Supreme Court regarding Sandoz’s Zarxio, a biosimilar of Amgen’s Neupogen, but it gained a different victory thanks to the FDA. Reuters reported that a biosimilar to Amgen’s Neulasta was not approved by the FDA. Neulasta is used to reduce the risk in patients with cancer of developing febrile neutropenia, a low count of neutrophils, which help the body fight infection. Coherus BioSciences’ biosimilar was not approved as the FDA requested a re-analysis of certain data. Neulasta currently generates about $4.6 billion in sales.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!